Microarray data has been deposited into the NCBI GEO database, accession number GSE116833.

Introduction {#sec001}
============

Cocaine use disorder (CUD) affects approximately 913,000 people aged 12 or older in the United States, and constitutes a substantial burden on the health care system \[[@pone.0207231.ref001],[@pone.0207231.ref002]\]. Many treatments have been attempted for CUD, including psychosocial therapies and various pharmaceutical interventions. However, psychosocial interventions show variable efficacy, and to date, no pharmaceutical interventions are FDA approved. Thus, further investigation of the psychopathological manifestations and causes of CUD is needed to develop more effective therapies. One approach may be to identify symptoms associated with poor treatment outcomes, and investigate the mechanisms underlying these symptoms. A better understanding of the biological and psychological underpinnings of these poor prognostic signs may critically assist the development of novel effective treatments for CUD.

One potential key symptom in addictive disorders in general, and CUD in particular, is anhedonia. Anhedonia is defined as a decrease in pleasure capacity; here we use it to refer more specifically to a loss of pleasure or interest in *non-drug* rewards. Anhedonia is common in addictive disorders, including cocaine, but also alcohol, opiate, amphetamine, and cannabis disorders \[[@pone.0207231.ref003],[@pone.0207231.ref004]\]. Across substances of abuse, the presence of anhedonia correlates with withdrawal symptom severity, craving, and likelihood of relapse, suggesting anhedonia may predict a more difficult course of addiction and worse treatment outcomes \[[@pone.0207231.ref003]\]. Several studies support the hypothesis that anhedonia is a poor prognostic sign in substance use disorders. For example, lifetime presence of anhedonia significantly predicts continued smoking during smoking cessation treatment, even after adjusting for the potential impact of co-occurring depressed mood \[[@pone.0207231.ref005]\]. Another study found that opiate dependent individuals who were less aroused by pleasant, non-drug related pictures were more likely to continue using heroin during treatment \[[@pone.0207231.ref006]\]. Most pertinent to CUD, low positive mood, measured using the Profile of Mood States (which could represent anhedonia), and the presence of anhedonia at treatment outset, as assessed using the Snaith-Hamilton Pleasure Scale, have been associated with poorer outcomes in CUD treatment \[[@pone.0207231.ref007],[@pone.0207231.ref008]\]. Therefore, understanding and addressing the pathological basis of anhedonia in CUD may help produce more effective treatments for CUD.

A significant body of literature suggests that inflammation, or excessive immune activity, may underlie anhedonia across disorders \[[@pone.0207231.ref009]--[@pone.0207231.ref011]\]. During acute inflammatory events, such as a cold, circulating inflammatory mediators produce "sickness behaviors" such as reduced activity, which serve the adaptive function of conserving energy and speeding healing \[[@pone.0207231.ref011]\]. However, maladaptive chronic low-grade inflammation appears to be present in many psychiatric disorders, and has been implicated in symptoms of anhedonia seen in depression, schizophrenia, and cancer-related fatigue, among other conditions \[[@pone.0207231.ref009],[@pone.0207231.ref012]--[@pone.0207231.ref014]\].

The neurological and biological mechanisms of anhedonia in CUD are not known, but one possibility is that cocaine use creates inflammation, which produces anhedonia. Some literature indicates inflammation is elevated in cocaine users, although findings are not fully consistent. In one study comparing crack cocaine users to healthy controls, users showed higher levels of the inflammatory mediators IL-1β, TNFα, and IL-10 \[[@pone.0207231.ref015]\]. A similar study indicated increases in IL-6 in cocaine users compared to healthy controls, although IL-10 was decreased in cocaine users \[[@pone.0207231.ref016]\]. Female crack cocaine users at the outset of treatment showed higher levels of IL-10, IL-4, and IL-6, which gradually moved closer to reference values throughout detoxification, indicating inflammation declines in conjunction with cocaine use \[[@pone.0207231.ref017]\]. A similar study of cocaine-using adolescents also found elevated IL-6 and IL-10 at treatment admission; however, in this study values did not change over treatment \[[@pone.0207231.ref018]\]. A study examining stress responses in cocaine users showed decreased basal IL-10 but enhanced TNFα responses to stress compared to social drinking controls \[[@pone.0207231.ref019]\]. However, other studies have either shown no differences in inflammatory biomarkers between individuals with CUD and controls \[[@pone.0207231.ref020]\], only shown differences in individuals with additional risk factors such as early life trauma \[[@pone.0207231.ref021]\], or even suggested immunosuppression in cocaine users \[[@pone.0207231.ref022]\]. Taken together, these mixed results suggest inflammation may be present only in a subset of cocaine users. We hypothesize these may be the same individuals who show anhedonia and more difficult clinical courses.

This study assessed peripheral genome-wide gene expression in individuals with CUD who were also displaying high levels of anhedonia, compared to individuals with CUD and low anhedonic symptoms. We examined gene expression in peripheral blood mononuclear cells, with the hypothesis that individuals with CUD and high levels of anhedonia would show different expression of genes in inflammatory pathways, compared to individuals with CUD and low levels of anhedonia. We assessed genome-wide expression for several reasons. First, gene expression shows promise as a peripheral biomarker of alterations in brain functioning, with studies suggesting that peripheral changes in expression, particularly in inflammatory pathways, relate to changes in brain tissue \[[@pone.0207231.ref023]\]. Further, a previous study in individuals with alcohol abuse discovered changes in the immune signaling pathways of alcohol abusers compared to healthy controls, suggesting this technique is sensitive to inflammatory changes in addiction \[[@pone.0207231.ref024]\]. We selected genome-wide analysis coupled with a bioinformatics approach because, as a complex condition, it is likely gene expression alterations in CUD are not limited to a few candidate genes, but rather to complex gene networks and potentially the accumulation of several unfavorable changes. Although the inflammation-anhedonia hypothesis has a strong theoretical basis, this exploratory approach was judged appropriate for an initial hypothesis-generating study that is the first to examine the biological underpinnings of anhedonia in CUD.

Materials and methods {#sec002}
=====================

Participants {#sec003}
------------

Participants were 48 individuals with Cocaine Dependence per DSM-IV or CUD of at least moderate severity per DSM-5 (this study bridged the transition from DSM-IV to DSM-5) attending screening sessions used to determine eligibility for both treatment and non-treatment studies at a center focused on treatment development for addictions. All participants provided separate written informed consent for data collection during the screening, including the blood draw and gene expression analyses, and all procedures were carried out in accordance with the Declaration of Helsinki and with the approval of the local Institutional Review Board at the University of Texas Health Science Center at Houston. Screening consisted of a Structured Clinical Interview for DSM-IV or DSM-5 \[[@pone.0207231.ref025],[@pone.0207231.ref026]\] and Addiction Severity Index--Lite \[[@pone.0207231.ref027]\] administered by a master's level clinician, a physical exam conducted by a physician, an electrocardiogram, laboratory tests, and completion of several self-report forms, including self-report of anhedonia. Criteria for inclusion in the gene expression study were: 1. No major inflammatory/medical conditions (e.g. tuberculosis, Hepatitis C, HIV, diabetes, active infection, cancer) with the exception of hypertension or high cholesterol; 2. No psychoactive or daily medication use, except for hypertension or high cholesterol medications; 3. No psychotic disorders; 4. If female, not pregnant, breastfeeding, peri- or post-menopausal, having a hysterectomy, or taking oral contraceptives. Participants with other psychiatric or substance use disorders were included, as significant comorbidity is typical in this population.

Self-report of anhedonia {#sec004}
------------------------

Our measure of anhedonia was the Snaith-Hamilton Pleasure Scale (SHAPS), which assesses ability to enjoy non-drug rewards \[[@pone.0207231.ref028]\]. The SHAPS is a 14-item, self-report scale that asks participants to indicate on a scale from 0 = \"Strongly Agree\" to 3 = \"Strongly Disagree\" their ability to enjoy 14 normally pleasurable events ("I would enjoy my favorite television or radio program" or "I would get pleasure from helping others"). Scores range from 0 to 42 with higher scores indicating greater anhedonia. The SHAPS is one of the most widely used self-reports of anhedonia, with good psychometric characteristics \[[@pone.0207231.ref029]\], and previous validation in a substance dependent population \[[@pone.0207231.ref030]\]. A median split of SHAPS scores was used to create high and low anhedonia groups for the gene expression analysis.

Genome-wide expression analysis {#sec005}
-------------------------------

Peripheral blood was collected from fasting participants in the morning (between 8am-12pm), by venipuncture into Heparin-containing vacutainers. This was followed by isolation of peripheral blood mononuclear cells with Ficoll-Paque (GE Healthcare, Little Chalfont, UK) density gradient centrifugation, as described by the manufacturer. Isolated cells (up to 3 x 10^6^ per vial) were resuspended in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA) containing 5% dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO) and stored at -80°C until further processed. RNA isolation was performed with the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. RNA quantification was performed on NanoDrop (Thermo Fisher Scientific) and the integrity of RNA samples was confirmed by assessing the RNA Integrity Number (RIN) using the RNA 6000 Nano Kit (Agilent, Santa Clara, CA) on Bioanalyzer (Agilent). Total RNA samples were converted into biotin-labeled cRNAs with the TargetAmp Nano Labeling Kit (Epicentre, Madison, WI), quantified on NanoDrop, and hybridized (750ng) to the HumanHT-12 v4 Expression BeadChip (Illumina, San Diego, CA), according to the manufacturer's instructions. BeadChips were scanned on an iScan microarray reader (Illumina) immediately after the hybridization protocol. Raw scan data were uploaded into the GenomeStudio software v2011.1 (Illumina), where they were initially background subtracted and quantile normalized using the Gene Expression Module v1.0. Microarray data has been deposited into the NCBI GEO database, accession number GSE116833.

Real-time quantitative PCR {#sec006}
--------------------------

The top two differentially expressed genes between groups were selected for validation using real time quantitative PCR. Briefly, RNA samples (160 ng) were initially converted into cDNA using the High Capacity cDNA Synthesis Kit (Life Technologies, Carlsbad, CA) and later diluted 5 times for the PCR reactions. Amplifications of Interferon Regulatory Factor 1 (*IRF1*) and Guanylate Binding Protein 5 (*GBP5*) were performed in 12 μL-reactions using inventoried FAM-MGB-labeled TaqMan Gene Expression Assays (Hs00971965_m1 and Hs00369472_m1 for *IRF1* and *GBP5*, respectively) and the VIC-MGB_PL-labelled beta-2-microglobulin (*B2M*) as endogenous control (Hs00187842_m1). PCR reactions were run on a QuantStudio 7 Flex Real-Time PCR System (Life Technologies) with each sample assayed in triplicate. Data were analyzed by the 2(-Delta Delta C(T)) method \[[@pone.0207231.ref031]\].

Statistical analysis {#sec007}
--------------------

Between-group *t*-tests and chi-squared tests with a significance level of *p* \< 0.05 were used to evaluate for possible group differences that might represent confounds. Genome-wide expression levels were compared between low and high anhedonia groups using GenomeStudio software v2011.1 (Illumina). Differential expression analysis between low and high anhedonia groups was performed using the low anhedonia as the reference group, 'Illumina custom' as the error model, and multiple testing correction using the Benjamini and Hochberg procedure to control for FDR. In addition to this stringent analysis, an exploratory analysis was performed to identify differentially expressed genes with nominal *p*-values \< 0.05. After checking for the normality of data on IBM SPSS Statistics 25 using Shapiro-Wilk's test and histogram visualization, we also investigated the correlation between the top-ranked differentially expressed genes and total SHAPS scores with the Spearman rank correlation coefficient. Differentially expressed genes were analyzed for their collective functional annotation on Database for Annotation, Visualization and Integrated Discovery (DAVID) version 6.8 \[[@pone.0207231.ref032]\]. The enriched functional annotation terms were selected based on a false discovery rate (FDR) cutoff \< 0.05.

Results {#sec008}
=======

Demographic data from CUD patients by group are shown in [Table 1](#pone.0207231.t001){ref-type="table"}. Groups did not significantly differ on any demographic, substance use or medical/psychiatric variables tested (p \> 0.05 for all comparisons). Race was collapsed into African-American vs. all others due to the small number of participants in other racial categories. In our sample the overall mean for the SHAPS was 11.68 (SD = 7.67), and the median split was at 11.5. This is similar to previous reports in individuals with substance use disorders \[[@pone.0207231.ref030]\], which tend to be above those of healthy adults, but below individuals with depression. Twenty seven percent of the sample met a previously established clinical cutoff for the presence of significant anhedonia on the SHAPS \[[@pone.0207231.ref028]\].

10.1371/journal.pone.0207231.t001

###### Demographic variables by group.

![](pone.0207231.t001){#pone.0207231.t001g}

  -------------------------------------------------------------------------------------------------------------------
  Variables                               Low Anhedonia Group\   High Anhedonia Group\   Statistic
                                          (N = 24)\              (N = 24)\               
                                          M (SD) or N (%)        M (SD) or N (%)         
  --------------------------------------- ---------------------- ----------------------- ----------------------------
  Demographic                                                                            

      Female gender                       5 (21%)                6 (25%)                 χ^2^(1) = 0.12, *p* = 0.73

      Age                                 44.12 (8.87)           47.50 (8.53)            t(46) = -1.34, *p* = 0.19

      African-American race               17 (71%)               20 (83%)                χ^2^(1) = 1.06, *p* = 0.30

      Years of education                  13.54 (1.84)           12.75 (1.89)            t(46) = 1.47, *p* = 0.15

  Substance Use                                                                          

      \# of days cocaine use past month   15.17 (9.12)           16.04 (8.98)            t(46) = -0.34, *p* = 0.74

      \# of years using cocaine           14.42 (10.61)          16.17 (9.30)            t(46) = -0.61, *p* = 0.55

      Cocaine+ UDS day of draw            16 Yes (67%)           19 Yes (79%)            χ^2^(1) = 0.95, *p* = 0.33

      Other Current SUD diagnosis         7 Yes (29%)            9 Yes (38%)             χ^2^(1) = 0.38, *p* = 0.54

  Medical/Psychiatric                                                                    

      Hypertension                        4 (17%)                4 (17%)                 χ^2^(1) = 0.00, *p* = 1.00

      Cholesterol mg/dl                   165.58 (30.10)         182.92 (46.66)          t(46) = -1.48, *p* = 0.15

      Fasting glucose mg/dl               85.21 (9.95)           84.04 (8.19)            t(46) = 0.44, *p* = 0.66

      Regular use of medications          9 (38%)                7 (29%)                 χ^2^(1) = 0.38, *p* = 0.54

      Other psychiatric diagnosis         6 (25%)                7 (29%)                 χ^2^(1) = 0.11, *p* = 0.75
  -------------------------------------------------------------------------------------------------------------------

Cocaine + UDS--Cocaine positive urine drug screen; SUD--Substance Use Disorder (including Alcohol Use Disorder); mg/dl--milligrams per deciliter.

No gene was significantly different between groups after correction for multiple testing (FDR-corrected *p* \> 0.05 for all comparisons). We found 166 differentially expressed genes or putative *loci* between groups in the exploratory analysis (nominal *p* \< 0.05), of which 41 were up-regulated and 125 were down-regulated in the high anhedonia group ([Table 2](#pone.0207231.t002){ref-type="table"}).

10.1371/journal.pone.0207231.t002

###### Differentially expressed genes in peripheral blood mononuclear cells from cocaine use disorder patients with low and high anhedonia (ranked by nominal *p*-value).

![](pone.0207231.t002){#pone.0207231.t002g}

  SYMBOL           Low anhedonia AVG   High anhedonia AVG   Nominal *p*-value   Fold change   Definition
  ---------------- ------------------- -------------------- ------------------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *IRF1*           1857.4              1365.6               0.00221             0.735         Homo sapiens interferon regulatory factor 1 (IRF1), mRNA.
  *GBP5*           1246.3              798.6                0.00288             0.640         Homo sapiens guanylate binding protein 5 (GBP5), mRNA.
  *KCTD10*         162.4               115.3                0.00479             0.709         Homo sapiens potassium channel tetramerisation domain containing 10 (KCTD10), mRNA.
  *PF4V1*          98.5                226.1                0.00506             2.295         Homo sapiens platelet factor 4 variant 1 (PF4V1), mRNA.
  *C1orf71*        774.6               1000.9               0.00529             1.292         Homo sapiens chromosome 1 open reading frame 71 (C1orf71), mRNA.
  *PID1*           199.9               304.7                0.00673             1.524         Homo sapiens phosphotyrosine interaction domain containing 1 (PID1), mRNA.
  *NLRC5*          92.4                69.6                 0.00766             0.753         Homo sapiens NLR family, CARD domain containing 5 (NLRC5), mRNA.
  *SRXN1*          480.8               377.7                0.0082              0.785         Homo sapiens sulfiredoxin 1 homolog (S. cerevisiae) (SRXN1), mRNA.
  *CXCL2*          541.9               235.1                0.00897             0.433         Homo sapiens chemokine (C-X-C motif) ligand 2 (CXCL2), mRNA.
  *SLC40A1*        428.3               555.8                0.01012             1.297         Homo sapiens solute carrier family 40 (iron-regulated transporter), member 1 (SLC40A1), mRNA.
  *PPP1R16B*       620.9               499.1                0.0111              0.803         Homo sapiens protein phosphatase 1, regulatory (inhibitor) subunit 16B (PPP1R16B), mRNA.
  *PDIA4*          46.6                31.9                 0.01143             0.684         Homo sapiens protein disulfide isomerase family A, member 4 (PDIA4), mRNA.
  *C1orf21*        43.3                23.1                 0.01242             0.533         Homo sapiens chromosome 1 open reading frame 21 (C1orf21), mRNA.
  *LAP3*           1230.5              920.8                0.01302             0.748         Homo sapiens leucine aminopeptidase 3 (LAP3), mRNA.
  *LOC441408*      94.4                73                   0.01321             0.773         PREDICTED: Homo sapiens hypothetical LOC441408, transcript variant 1 (LOC441408), mRNA.
  *TMEM170A*       161.8               127.6                0.01329             0.788         Homo sapiens transmembrane protein 170A (TMEM170A), mRNA.
  *PRIC285*        761.8               556.4                0.01379             0.730         Homo sapiens peroxisomal proliferator-activated receptor A interacting complex 285 (PRIC285), transcript variant 2, mRNA.
  *FCHSD2*         231.3               188.6                0.01382             0.815         Homo sapiens FCH and double SH3 domains 2 (FCHSD2), mRNA.
  *PRC1*           71.5                51.6                 0.01388             0.721         Homo sapiens protein regulator of cytokinesis 1 (PRC1), transcript variant 2, mRNA.
  *SH3BGRL2*       285                 425                  0.01453             1.49          Homo sapiens SH3 domain binding glutamic acid-rich protein like 2 (SH3BGRL2), mRNA.
  *CD55*           284.9               226.8                0.01486             0.796         Homo sapiens CD55 molecule, decay accelerating factor for complement (Cromer blood group) (CD55), mRNA.
  *PDK4*           228.5               371.1                0.01529             1.624         Homo sapiens pyruvate dehydrogenase kinase, isozyme 4 (PDK4), mRNA.
  *FLJ33590*       87.2                58.4                 0.0153              0.669         Homo sapiens hypothetical protein FLJ33590 (FLJ33590), mRNA.
  *SNCA*           208.6               277.4                0.01562             1.329         Homo sapiens synuclein, alpha (non A4 component of amyloid precursor) (SNCA), transcript variant NACP112, mRNA.
  *SPATS2L*        177.6               122                  0.0163              0.686         Homo sapiens spermatogenesis associated, serine-rich 2-like (SPATS2L), transcript variant 2, mRNA.
  *STAT1*          2174                1456.3               0.01725             0.669         Homo sapiens signal transducer and activator of transcription 1, 91kDa (STAT1), transcript variant alpha, mRNA.
  *TGFBR3*         1661.2              1222.6               0.01767             0.735         Homo sapiens transforming growth factor, beta receptor III (TGFBR3), mRNA.
  *ARL4C*          208.3               163.1                0.01783             0.783         Homo sapiens ADP-ribosylation factor-like 4C (ARL4C), mRNA.
  *RIPK2*          1123.6              846.9                0.01787             0.753         Homo sapiens receptor-interacting serine-threonine kinase 2 (RIPK2), mRNA.
  *IFITM3*         3464.5              1863.3               0.01793             0.537         Homo sapiens interferon induced transmembrane protein 3 (1-8U) (IFITM3), mRNA.
  *DUSP5*          1234.6              950.5                0.01852             0.769         Homo sapiens dual specificity phosphatase 5 (DUSP5), mRNA.
  *C17orf97*       48.9                88.5                 0.01864             1.809         Homo sapiens chromosome 17 open reading frame 97 (C17orf97), mRNA.
  *CYLN2*          52.7                73                   0.01948             1.385         Homo sapiens cytoplasmic linker 2 (CYLN2), transcript variant 2, mRNA.
  *RGS18*          1318.6              1720.1               0.01965             1.304         Homo sapiens regulator of G-protein signaling 18 (RGS18), mRNA.
  *BCAT1*          61.4                86.3                 0.02051             1.405         Homo sapiens branched chain aminotransferase 1, cytosolic (BCAT1), mRNA.
  *TAP1*           3242.5              2637.6               0.0215              0.813         Homo sapiens transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) (TAP1), mRNA.
  *HERC5*          955.6               644.8                0.02163             0.674         Homo sapiens hect domain and RLD 5 (HERC5), mRNA.
  *APOBEC3H*       51.9                30.8                 0.02165             0.593         Homo sapiens apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3H (APOBEC3H), mRNA.
  *KLF5*           24.2                11.1                 0.02191             0.458         Homo sapiens Kruppel-like factor 5 (intestinal) (KLF5), mRNA.
  *LBA1*           311.2               255.4                0.02252             0.820         Homo sapiens lupus brain antigen 1 (LBA1), mRNA.
  *ZMYND15*        94.3                68.5                 0.02335             0.726         Homo sapiens zinc finger, MYND-type containing 15 (ZMYND15), transcript variant 2, mRNA.
  *HERC6*          295.6               215.7                0.02347             0.729         Homo sapiens hect domain and RLD 6 (HERC6), transcript variant 1, mRNA.
  *PFN4*           4                   14.4                 0.02409             3.6           Homo sapiens profilin family, member 4 (PFN4), mRNA.
  *KIAA1600*       473.5               393.3                0.02432             0.830         Homo sapiens KIAA1600 (KIAA1600), mRNA.
  *RGS1*           643.7               370.8                0.02467             0.576         Homo sapiens regulator of G-protein signaling 1 (RGS1), mRNA.
  *SLC25A28*       1486.8              1259.1               0.02474             0.846         Homo sapiens solute carrier family 25, member 28 (SLC25A28), mRNA.
  *NAPB*           134.8               109.6                0.0249              0.813         Homo sapiens N-ethylmaleimide-sensitive factor attachment protein, beta (NAPB), mRNA.
  *C20orf3*        718.3               606.4                0.02518             0.844         Homo sapiens chromosome 20 open reading frame 3 (C20orf3), mRNA.
  *USP18*          44                  16.8                 0.02551             0.3818        Homo sapiens ubiquitin specific peptidase 18 (USP18), mRNA.
  *NCOA7*          853.7               674.2                0.02568             0.789         Homo sapiens nuclear receptor coactivator 7 (NCOA7), mRNA.
  *MYBPC3*         43.6                30.2                 0.02598             0.692         Homo sapiens myosin binding protein C, cardiac (MYBPC3), mRNA.
  *DGKE*           25.8                14.5                 0.02606             0.562         Homo sapiens diacylglycerol kinase, epsilon 64kDa (DGKE), mRNA.
  *LOC100132503*   68.6                88.3                 0.02656             1.287         PREDICTED: Homo sapiens similar to ring finger protein 208 (LOC100132503), mRNA.
  *LOC400759*      126.3               70                   0.02685             0.554         Homo sapiens similar to Interferon-induced guanylate-binding protein 1 (GTP-binding protein 1) (Guanine nucleotide-binding protein 1) (HuGBP-1) (LOC400759) on chromosome 1.
  *LOC197135*      201.7               128.4                0.02699             0.636         PREDICTED: Homo sapiens hypothetical LOC197135, transcript variant 5 (LOC197135), mRNA.
  *REC8*           251.1               194.2                0.02707             0.773         Homo sapiens REC8 homolog (yeast) (REC8), transcript variant 1, mRNA.
  *NFIL3*          946                 707.4                0.02725             0.747         Homo sapiens nuclear factor, interleukin 3 regulated (NFIL3), mRNA.
  *LOC729580*      88.3                69                   0.02736             0.781         PREDICTED: Homo sapiens hypothetical LOC729580 (LOC729580), mRNA.
  *C16orf33*       389.5               327.8                0.02783             0.841         Homo sapiens chromosome 16 open reading frame 33 (C16orf33), mRNA.
  *CD8A*           2691                2060.5               0.02813             0.765         Homo sapiens CD8a molecule (CD8A), transcript variant 2, mRNA.
  *LRRC57*         122.4               99.2                 0.02817             0.810         Homo sapiens leucine rich repeat containing 57 (LRRC57), mRNA.
  *CD83*           1912                1345.2               0.0283              0.703         Homo sapiens CD83 molecule (CD83), transcript variant 1, mRNA.
                   673.5               556.7                0.02839             0.826         full-length cDNA clone CS0CAP005YH21 of Thymus of Homo sapiens (human)
                   248                 194.4                0.02872             0.783         Homo sapiens cDNA clone IMAGE:5277162
  *F13A1*          659.8               875                  0.02876             1.326         Homo sapiens coagulation factor XIII, A1 polypeptide (F13A1), mRNA.
  *NECAP1*         563.1               473.3                0.02878             0.840         Homo sapiens NECAP endocytosis associated 1 (NECAP1), mRNA.
                   12.1                23.6                 0.02931             1.950         Human tissue plasminogen activator mRNA, partial cds
                   31.1                19.7                 0.02958             0.633         Homo sapiens cDNA FLJ35432 fis, clone SMINT2002311
  *LOC648470*      345.6               281.4                0.02995             0.814         PREDICTED: Homo sapiens similar to Caspase-4 precursor (CASP-4) (ICH-2 protease) (TX protease) (ICE(rel)-II) (LOC648470), mRNA.
  *GBP4*           760.3               544.7                0.03006             0.716         Homo sapiens guanylate binding protein 4 (GBP4), mRNA.
  *EPSTI1*         1084.5              642.8                0.03101             0.592         Homo sapiens epithelial stromal interaction 1 (breast) (EPSTI1), transcript variant 2, mRNA.
  *FAM50B*         52.2                72.4                 0.03109             1.386         Homo sapiens family with sequence similarity 50, member B (FAM50B), mRNA.
  *HSH2D*          257.2               202.8                0.03133             0.788         Homo sapiens hematopoietic SH2 domain containing (HSH2D), mRNA.
  *LOC644590*      328.2               276.6                0.03143             0.842         PREDICTED: Homo sapiens similar to EVIN1 (LOC644590), mRNA.
  *PSME2*          2178.8              1812.5               0.03168             0.831         Homo sapiens proteasome (prosome, macropain) activator subunit 2 (PA28 beta) (PSME2), mRNA.
  *LOC649864*      54.2                39.7                 0.03174             0.732         PREDICTED: Homo sapiens similar to HLA class I histocompatibility antigen, A-29 alpha chain precursor (MHC class I antigen A\*29) (Aw-19), transcript variant 1 (LOC649864), mRNA.
  *KDELC2*         146.1               119.6                0.03215             0.818         Homo sapiens KDEL (Lys-Asp-Glu-Leu) containing 2 (KDELC2), mRNA.
  *UAP1*           293                 245.3                0.03287             0.837         Homo sapiens UDP-N-acteylglucosamine pyrophosphorylase 1 (UAP1), mRNA.
  *CLCF1*          102.4               80.9                 0.03289             0.790         Homo sapiens cardiotrophin-like cytokine factor 1 (CLCF1), transcript variant 1, mRNA.
  *IBSP*           9.4                 19.9                 0.03293             2.117         Homo sapiens integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II) (IBSP), mRNA.
  *C9orf82*        97.9                78.6                 0.03309             0.802         Homo sapiens chromosome 9 open reading frame 82 (C9orf82), mRNA.
  *PGA5*           5.4                 19.8                 0.03319             3.666         Homo sapiens pepsinogen 5, group I (pepsinogen A) (PGA5), mRNA.
  *ITM2C*          776.2               638.7                0.03364             0.822         Homo sapiens integral membrane protein 2C (ITM2C), transcript variant 2, mRNA.
  *TRIM22*         976.5               775.9                0.03373             0.794         Homo sapiens tripartite motif-containing 22 (TRIM22), mRNA.
  *SNORD114-2*     24.1                35.6                 0.03385             1.477         Homo sapiens small nucleolar RNA, C/D box 114--2 (SNORD114-2), small nucleolar RNA.
  *LAPTM4B*        67.1                89                   0.03442             1.326         Homo sapiens lysosomal protein transmembrane 4 beta (LAPTM4B), mRNA.
  *FAM46C*         1498.2              1164.3               0.03446             0.777         Homo sapiens family with sequence similarity 46, member C (FAM46C), mRNA.
  *SLAMF7*         138.5               104                  0.03478             0.750         Homo sapiens SLAM family member 7 (SLAMF7), mRNA.
  *KBTBD8*         200.4               163.8                0.03491             0.817         Homo sapiens kelch repeat and BTB (POZ) domain containing 8 (KBTBD8), mRNA.
  *IRF4*           185.1               152.3                0.03537             0.822         Homo sapiens interferon regulatory factor 4 (IRF4), mRNA.
  *FFAR2*          63.5                35.4                 0.03551             0.557         Homo sapiens free fatty acid receptor 2 (FFAR2), mRNA.
  *TDRD9*          47.7                66.9                 0.03554             1.402         Homo sapiens tudor domain containing 9 (TDRD9), mRNA.
  *FBXO6*          295.5               232                  0.03571             0.785         Homo sapiens F-box protein 6 (FBXO6), mRNA.
  *IL12A*          34.6                21.7                 0.03571             0.627         Homo sapiens interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35) (IL12A), mRNA.
  *GALM*           148.3               120.8                0.036               0.814         Homo sapiens galactose mutarotase (aldose 1-epimerase) (GALM), mRNA.
  *PATL2*          182                 116.5                0.03614             0.640         PREDICTED: Homo sapiens misc_RNA (PATL2), miscRNA.
  *IFI44*          973.5               556.6                0.03638             0.571         Homo sapiens interferon-induced protein 44 (IFI44), mRNA.
  *TNFRSF21*       156.3               111.6                0.03707             0.714         Homo sapiens tumor necrosis factor receptor superfamily, member 21 (TNFRSF21), mRNA.
  *GNG11*          899.5               1303.2               0.03713             1.448         Homo sapiens guanine nucleotide binding protein (G protein), gamma 11 (GNG11), mRNA.
  *TMEM88*         43.6                27.2                 0.03735             0.623         Homo sapiens transmembrane protein 88 (TMEM88), mRNA.
  *NRGN*           1413                1980.4               0.03751             1.401         Homo sapiens neurogranin (protein kinase C substrate, RC3) (NRGN), mRNA.
  *LOC100133583*   1081.4              870.6                0.03818             0.805         PREDICTED: Homo sapiens similar to major histocompatibility complex, class II, DQ beta 1, transcript variant 2 (LOC100133583), mRNA.
  *GABARAPL1*      536.9               417.1                0.03826             0.776         Homo sapiens GABA(A) receptor-associated protein like 1 (GABARAPL1), mRNA.
  *PTGFRN*         13.2                24                   0.03829             1.818         Homo sapiens prostaglandin F2 receptor negative regulator (PTGFRN), mRNA.
  *PDXK*           436.9               514.6                0.0385              1.177         Homo sapiens pyridoxal (pyridoxine, vitamin B6) kinase (PDXK), mRNA.
  *ATG2A*          339.2               287.2                0.0385              0.846         Homo sapiens ATG2 autophagy related 2 homolog A (S. cerevisiae) (ATG2A), mRNA.
  *TAGAP*          330.2               259                  0.0393              0.784         Homo sapiens T-cell activation RhoGTPase activating protein (TAGAP), transcript variant 2, mRNA.
  *NAT8B*          127.4               184.4                0.03936             1.447         Homo sapiens N-acetyltransferase 8B (GCN5-related, putative, gene/pseudogene) (NAT8B), mRNA.
  *C19orf33*       23.3                42.5                 0.0396              1.824         Homo sapiens chromosome 19 open reading frame 33 (C19orf33), mRNA.
  *MYLIP*          1777.6              1479.2               0.03961             0.832         Homo sapiens myosin regulatory light chain interacting protein (MYLIP), mRNA.
  *ANKRD27*        113.7               93.1                 0.03962             0.818         Homo sapiens ankyrin repeat domain 27 (VPS9 domain) (ANKRD27), mRNA.
  *PATL1*          853.9               731.7                0.03985             0.856         Homo sapiens protein associated with topoisomerase II homolog 1 (yeast) (PATL1), mRNA.
  *MCL1*           1439.3              1263.9               0.03995             0.878         Homo sapiens myeloid cell leukemia sequence 1 (BCL2-related) (MCL1), transcript variant 1, mRNA.
  *LOC643733*      107.4               87.4                 0.04028             0.813         PREDICTED: Homo sapiens hypothetical LOC643733 (LOC643733), mRNA.
  *S1PR5*          811.2               591                  0.04044             0.728         Homo sapiens sphingosine-1-phosphate receptor 5 (S1PR5), mRNA.
  *GNLY*           3203.7              2308.7               0.04079             0.720         Homo sapiens granulysin (GNLY), transcript variant NKG5, mRNA.
  *C17orf56*       96.3                77.7                 0.04085             0.806         Homo sapiens chromosome 17 open reading frame 56 (C17orf56), mRNA.
  *PCNT*           594.2               500.2                0.04122             0.841         Homo sapiens pericentrin (PCNT), mRNA.
  *GFI1*           217.8               168.2                0.04128             0.772         Homo sapiens growth factor independent 1 transcription repressor (GFI1), mRNA.
  *GLTPD1*         36.1                48.6                 0.04149             1.346         Homo sapiens glycolipid transfer protein domain containing 1 (GLTPD1), mRNA.
  *SLC25A4*        154.7               126.6                0.04161             0.818         Homo sapiens solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 (SLC25A4), nuclear gene encoding mitochondrial protein, mRNA.
  *HBEGF*          839.1               550.7                0.0417              0.656         Homo sapiens heparin-binding EGF-like growth factor (HBEGF), mRNA.
  *FAM179A*        128.1               91.4                 0.04173             0.713         Homo sapiens family with sequence similarity 179, member A (FAM179A), mRNA.
  *TNFAIP3*        2436.9              1817.1               0.04194             0.745         Homo sapiens tumor necrosis factor, alpha-induced protein 3 (TNFAIP3), mRNA.
  *GBP2*           3234.4              2664.8               0.04267             0.823         Homo sapiens guanylate binding protein 2, interferon-inducible (GBP2), mRNA.
  *TRIM11*         186.6               156.9                0.04292             0.840         Homo sapiens tripartite motif-containing 11 (TRIM11), mRNA.
  *MAFB*           3522                2710.3               0.04307             0.769         Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) (MAFB), mRNA.
  *CEBPA*          755.7               907.2                0.04315             1.200         Homo sapiens CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA), mRNA.
  *GBP1*           592.5               334.1                0.0434              0.563         Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA.
  *FANCG*          154.3               128.9                0.04358             0.835         Homo sapiens Fanconi anemia, complementation group G (FANCG), mRNA.
  *C1orf166*       215.1               181.7                0.04383             0.844         Homo sapiens chromosome 1 open reading frame 166 (C1orf166), mRNA.
  *OTUD1*          563.3               444.8                0.04392             0.789         PREDICTED: Homo sapiens OTU domain containing 1 (OTUD1), mRNA.
  *RNASE6*         712.7               850.7                0.04399             1.193         Homo sapiens ribonuclease, RNase A family, k6 (RNASE6), mRNA.
  *IL18R1*         326.3               274.9                0.04408             0.842         Homo sapiens interleukin 18 receptor 1 (IL18R1), mRNA.
  *FAM82A2*        661.2               567.8                0.04481             0.858         Homo sapiens family with sequence similarity 82, member A2 (FAM82A2), mRNA.
  *ITPRIP*         823.8               701                  0.04497             0.850         Homo sapiens inositol 1,4,5-triphosphate receptor interacting protein (ITPRIP), mRNA.
  *TM6SF1*         158.5               196.8                0.04506             1.241         Homo sapiens transmembrane 6 superfamily member 1 (TM6SF1), mRNA.
  *SH2D2A*         111.2               91.5                 0.04507             0.822         Homo sapiens SH2 domain protein 2A (SH2D2A), mRNA.
  *TBC1D8*         164.6               133.6                0.04512             0.811         Homo sapiens TBC1 domain family, member 8 (with GRAM domain) (TBC1D8), mRNA.
  *KBTBD2*         780.8               668.5                0.04523             0.856         Homo sapiens kelch repeat and BTB (POZ) domain containing 2 (KBTBD2), mRNA.
  *LOC728835*      1550.2              788.3                0.04542             0.508         PREDICTED: Homo sapiens similar to cytokine, transcript variant 3 (LOC728835), mRNA.
  *DDX60*          282.4               208.8                0.04543             0.739         Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (DDX60), mRNA.
  *HLA-G*          1282.7              1105.5               0.04544             0.861         Homo sapiens HLA-G histocompatibility antigen, class I, G (HLA-G), mRNA.
  *TXNDC11*        263.6               223.9                0.04555             0.849         Homo sapiens thioredoxin domain containing 11 (TXNDC11), mRNA.
  *SYTL1*          359.6               307                  0.04565             0.853         Homo sapiens synaptotagmin-like 1 (SYTL1), mRNA.
  *CCL4L1*         1781.5              845.5                0.04659             0.474         Homo sapiens chemokine (C-C motif) ligand 4-like 1 (CCL4L1), mRNA.
  *PARP12*         374.2               299.3                0.04667             0.799         Homo sapiens poly (ADP-ribose) polymerase family, member 12 (PARP12), mRNA.
  *ACTN1*          1248.3              1617.6               0.04701             1.295         Homo sapiens actinin, alpha 1 (ACTN1), mRNA.
  *TST*            683.6               805.1                0.04719             1.177         Homo sapiens thiosulfate sulfurtransferase (rhodanese) (TST), nuclear gene encoding mitochondrial protein, mRNA.
  *ZNF366*         8.7                 17.7                 0.04733             2.034         Homo sapiens zinc finger protein 366 (ZNF366), mRNA.
  *CCL2*           335.1               178.2                0.04737             0.531         Homo sapiens chemokine (C-C motif) ligand 2 (CCL2), mRNA.
  *RNF10*          415.4               350.3                0.04757             0.843         Homo sapiens ring finger protein 10 (RNF10), mRNA.
  *FCER1A*         1459.3              1873.7               0.04808             1.283         Homo sapiens Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide (FCER1A), mRNA.
  *IFI44L*         662.6               264.8                0.04823             0.399         Homo sapiens interferon-induced protein 44-like (IFI44L), mRNA.
  *C1orf177*       26.2                37.2                 0.04823             1.419         Homo sapiens chromosome 1 open reading frame 177 (C1orf177), mRNA.
  *OAS3*           435.9               272.1                0.04838             0.624         Homo sapiens 2\'-5\'-oligoadenylate synthetase 3, 100kDa (OAS3), mRNA.
  *LOC728006*      140.1               170.1                0.04866             1.214         PREDICTED: Homo sapiens hypothetical protein LOC728006 (LOC728006), mRNA.
  *ATP6V0A1*       489.6               577.4                0.04873             1.179         Homo sapiens ATPase, H+ transporting, lysosomal V0 subunit a1 (ATP6V0A1), transcript variant 3, mRNA.
  *SLC2A1*         494.2               421.3                0.04882             0.852         Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1), mRNA.
  *SPOCD1*         23.6                42.4                 0.04902             1.796         Homo sapiens SPOC domain containing 1 (SPOCD1), mRNA.
  *IDI1*           435.2               348.6                0.04916             0.801         Homo sapiens isopentenyl-diphosphate delta isomerase 1 (IDI1), mRNA.
  *SERPINF1*       56.9                40.1                 0.04927             0.704         Homo sapiens serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 (SERPINF1), mRNA.
  *CDC45L*         32                  18.4                 0.04934             0.575         Homo sapiens CDC45 cell division cycle 45-like (S. cerevisiae) (CDC45L), mRNA.
  *KLHDC5*         203.5               247.7                0.04958             1.217         Homo sapiens kelch domain containing 5 (KLHDC5), mRNA.
  *KLRG1*          407.4               294.4                0.0497              0.722         Homo sapiens killer cell lectin-like receptor subfamily G, member 1 (KLRG1), mRNA.
  *LOC728276*      -1.5                6.5                  0.04973             4.333         PREDICTED: Homo sapiens similar to Lithostathine 1 precursor (Pancreatic stone protein 1) (PSP) (Pancreatic thread protein 1) (PTP) (Islet of Langerhans regenerating protein 1) (REG 1) (LOC728276), mRNA.

AVG--average. Fold change values lower than 1 represent down-regulation of the gene in the high anhedonia group compared to low anhedonia group, while values higher than 1 represent up-regulation.

The top differentially expressed genes were *IRF1* (*p* = 0.00221) and *GBP5* (*p* = 0.00288), which were both significantly downregulated in the high anhedonia group ([Fig 1A and 1B](#pone.0207231.g001){ref-type="fig"}). Significant correlations were found between microarray expression of both genes and the total SHAPS score (*IRF1* --*r*~*s*~ = -0.378, *p* = 0.008; *GBP5* --*r*~*s*~ = -0.330, *p* = 0.022, [Fig 1C and 1D](#pone.0207231.g001){ref-type="fig"}). Findings from the microarray were partly validated by qPCR, with measures of *IRF1* and *GBP5* obtained from both methods showing significant correlations ([S1 Fig](#pone.0207231.s001){ref-type="supplementary-material"}). However, the relationships between these individual genes and anhedonia did not sustain statistical significance when gene expression was measured by qPCR data, although trends were similar (*IRF1* --Mann-Whitney U = 210, *p* = 0.108; *GBP5* --U = 197, *p* = 0.061; [S2 Fig](#pone.0207231.s002){ref-type="supplementary-material"}).

![Gene expression of interferon regulatory factor 1 (IRF1) and guanylate binding protein 5 (GBP5) in peripheral blood mononuclear cells from patients with cocaine use disorder with low and high symptoms of anhedonia.\
A and B) Between-group comparison of *IRF1* (A) and *GBP5* (B) expression values. Dots represent individual values for each subject and lines represent mean ± standard deviation. Comparisons were made with Mann-Whitney U tests. C and D) Spearman's rank-order correlation between total Snaith-Hamilton Pleasure Scale (SHAPS) scores and the expression of *IRF1* (C) and *GBP5* (D).](pone.0207231.g001){#pone.0207231.g001}

Pathway analysis performed on DAVID showed that the 166 differentially expressed genes were enriched for mechanisms related to defense response to virus, antiviral defense, immunity, interferon-gamma-mediated signaling pathway, among others ([Table 3](#pone.0207231.t003){ref-type="table"}). Functional annotation clustering analysis was also performed to reduce the redundancy of our findings and confirmed mechanisms related to immunity as the top-relevant pathways associated with anhedonia in our sample ([S1 Table](#pone.0207231.s003){ref-type="supplementary-material"}).

10.1371/journal.pone.0207231.t003

###### Pathway analysis (functional annotation) of the nominally differentially expressed genes (n = 166) between cocaine use disorder patients with low and high anhedonia.

![](pone.0207231.t003){#pone.0207231.t003g}

  Category           Term                                          Count   \%     P-value   FDR
  ------------------ --------------------------------------------- ------- ------ --------- --------
  GOTERM_BP_DIRECT   defense response to virus                     13      9,6    2,1E-9    3,2E-6
  UP_KEYWORDS        Antiviral defense                             11      8,1    3,8E-9    4,8E-6
  UP_KEYWORDS        Immunity                                      18      13,3   2,2E-8    2,8E-5
  GOTERM_BP_DIRECT   interferon-gamma-mediated signaling pathway   8       5,9    6,9E-7    1,1E-3
  GOTERM_BP_DIRECT   immune response                               15      11,1   1,7E-6    2,6E-3
  GOTERM_BP_DIRECT   type I interferon signaling pathway           7       5,2    6,0E-6    9,3E-3
  UP_KEYWORDS        Innate immunity                               11      8,1    7,3E-6    9,1E-3

Gene-term enrichment performed on DAVID v. 6.8 (<https://david.ncifcrf.gov/>). The most relevant (overrepresented) biological terms associated with the list of differentially expressed genes were identified by the DAVID functional annotation chart. Enrichments were calculated with a modified Fisher's exact test controlled for false discovery rate (FDR).

Discussion {#sec009}
==========

In this study, we examined genome-wide gene expression in peripheral blood mononuclear cells, with the hypothesis that participants with CUD and high levels of anhedonia would display a unique expression of inflammatory pathways, compared to individuals with CUD and low anhedonic symptoms. No individual genes were determined to be significantly different between the low and high anhedonia groups using stringent controls for false discovery rate. However, an exploratory analysis to identify differentially expressed genes with nominal *p* \< 0.05 found 166 putative *loci* that differed between groups. DAVID, a bioinformatics tool that provides functional interpretations of complex lists of genes, was utilized to examine representation of these top differentially expressed genes in known gene pathways. It confirmed that mechanisms related to immunity were the most pertinent pathways corresponding with anhedonia in our sample. The two top differentially expressed genes in our sample were chosen for additional validation. These were *IRF1* and *GBP5*; genes related to transcriptional regulation, tumor response, inflammation, and innate immunity. Expression of both genes significantly correlated with total scores on our self-report of anhedonia, further substantiating the relationship of these gene expression changes to anhedonia.

Several studies have linked cocaine use to inflammatory mechanisms \[[@pone.0207231.ref015],[@pone.0207231.ref033]\]. However, our results suggest that some CUD patients display greater changes in inflammatory markers than others, suggesting a more complex and heterogeneous association between CUD and inflammation. In particular, these alterations in immune functioning were associated with a poor prognostic sign for CUD, anhedonia. Based on these results, it seems possible that a subset of patients with CUD present a pro-inflammatory genetic profile that interacts with cocaine use or other associated environmental factors to promote an anhedonic (and treatment-resistant) phenotype. Although our groups did not differ on basic demographics or measures of drug use, these changes may also be reflective of subtler differences in intensity or frequency of cocaine use, unmeasured environmental or psychosocial factors, biological and genetic differences, or gene by environment interactions, as seen with other genetic variants in addiction \[[@pone.0207231.ref034],[@pone.0207231.ref035]\]. Our study is the first to provide preliminary evidence for the hypothesis that anhedonia in CUD is related to inflammatory changes in gene-expression, but a more in-depth assessment in a larger sample size that could include examination of potential gene *vs*. environment interactions is warranted.

As hypothesized, the top-ranked pathways associated with the differentially expressed genes in our sample were all linked to inflammatory mechanisms. Further, both top differentially expressed genes have immune-related functions. *IRF1* serves as a transcriptional activator of several genes involved in both innate and acquired immune responses, as well as in tissue response to inflammation, cell proliferation, and programmed cell death \[[@pone.0207231.ref036]--[@pone.0207231.ref038]\]. The relationship of *IRF1* to cocaine use is unknown, but it could plausibly be modulated by dopamine-enhancing properties of cocaine and the cellular signaling pathways that are activated by both D1- and D2-like dopamine receptors after cocaine use \[[@pone.0207231.ref039]\]. Dopamine receptor D1 is known to activate protein kinase A (PKA), which in turn can serine-phosphorylate IRF1 \[[@pone.0207231.ref040]\]. Once phosphorylated, IRF1 has been shown to activate IFN-α/β promoters to induce their endogenous expressions \[[@pone.0207231.ref041]--[@pone.0207231.ref043]\], ultimately affecting the immune/inflammatory response \[[@pone.0207231.ref044]\]. Moreover, cocaine use has been associated with alterations in the levels of leptin \[[@pone.0207231.ref045]\], which is an adipokine produced by both the adipose tissue and immune cells and participates in innate and adaptive immunity \[[@pone.0207231.ref046]\]. Interestingly, leptin has been shown to promote the activation and recruitment of a transcriptional complex between IRF1 and CREB \[[@pone.0207231.ref047]\], suggesting another layer of regulation by which cocaine could interfere with IRF-1 mechanisms and ultimately regulate inflammation. Similarly, *GBP5*'s expression is not only induced by IFN-γ \[[@pone.0207231.ref048]\], but is also an activator of the NLRP3 inflammasome \[[@pone.0207231.ref049]\], with key roles in innate immunity and overall inflammation \[[@pone.0207231.ref050]\]. There is no reported evidence of a direct effect of cocaine or the activation of dopamine receptors on the expression or function of GBP5, limiting the further interpretation of the relationship of this factor to cocaine use. Our study is the first to report altered levels of these gene transcripts both in CUD and in relation to anhedonia. Both genes were found to be downregulated in high anhedonia CUD patients compared to those with low anhedonia, suggesting a dysfunction in inflammatory mechanisms in these patients. Interestingly, IRF-1 is also downregulated by stress-related hormones \[[@pone.0207231.ref051]\], consistent with hypotheses that drug use and stress produce similar and synergistic effects on immune responses \[[@pone.0207231.ref052]\], and hypotheses linking excessive inflammatory responses to stress with anhedonia \[[@pone.0207231.ref053]\]. Further, one study found that chronic methamphetamine administration in mice resulted in downregulation of GBP-5 expression in the nucleus accumbens. Together these findings support our results by suggesting that although the identification of these transcripts in CUD is novel, they are affected in consistent directions by other stressors, including other stimulant drugs.

There has been increasing recognition of the value of using genome-wide transcription profiles to drive medication development in addiction, with examples in both alcohol use disorder \[[@pone.0207231.ref054]\] and methamphetamine use disorder \[[@pone.0207231.ref055]\]. Although our top gene candidates are not part of the "druggable genome" that can be directly targeted with already-developed compounds, our results nevertheless suggest critical future directions for CUD treatment research. Specifically, medication development efforts in CUD have often focused on agonist strategies using stimulant medications \[[@pone.0207231.ref056]\], but these medications may themselves have inflammatory effects, resulting in poor outcomes for individuals with an anhedonic/inflammatory profile. Our research suggests that prioritizing anti-inflammatory medications in development for stimulant use disorders, such as pioglitazone \[[@pone.0207231.ref057]\] and ibudilast \[[@pone.0207231.ref058]\], may pay dividends, particularly in combination with treatment-matching strategies using either the anhedonic phenotype or biomarkers of inflammatory gene expression to personalize treatment. Interestingly, a recent study found that an improvement in the hedonic tone induced by repetitive transcranial magnetic stimulation (rTMS) in CUD patients was associated with a reduction in the craving for cocaine \[[@pone.0207231.ref059]\]. A future direction for research may be to explore whether these improvements are associated with inflammatory alterations, and whether the inflammatory genes identified in our study may be able to predict outcomes in treatments like this that are directed at ameliorating anhedonia in CUD patients.

Our results need to be interpreted in light of some limitations. First, the relationship between peripheral and central changes in gene expression and/or inflammation is ultimately unknown. Although research suggests some substantive correspondences between peripheral and central gene expression \[[@pone.0207231.ref023]\], our top candidates are not among those transcripts with confirmed peripheral/central relationships. It is also the case that we do not know the degree to which the observed mRNA alterations relate to altered production of inflammatory compounds in the brain or periphery. Future studies should focus on the correlation of our identified inflammatory markers between blood and brain to allow a further discussion and more accurate interpretation of our findings, especially as they may relate to neuroinflammation or systemic inflammation. Although prior studies suggest a relationship between *increased* inflammation and anhedonia, we found *downregulation* of two genes generally presumed to be pro-inflammatory. In the absence of more direct measures of the state of either peripheral or central immune functioning in these participants, these results do not allow us to directly infer the presence of inflammation, only that immune functioning appears to differ between our groups. There are also limitations inherent in measuring genome-wide expression via a microarray, which is restricted to the probes available in the Beadchip and may not capture the full snapshot of gene expression alterations in CUD \[[@pone.0207231.ref060]\]. In addition, our analysis did not allow for the detection of specific transcripts derived from the same gene, which might have masked important information regarding alternative splicing mechanisms and their potential involvement in anhedonia \[[@pone.0207231.ref023]\]. A network-based approach assessing the interaction between several genes and transcripts detected by next-generation sequencing techniques might provide more comprehensive and biologically-relevant results in the future. In this sense, to actually confirm our microarray results and explore their full clinical implications, the findings obtained in this analysis (which were only partially replicated by qPCR) require further biological validation by the measurement of protein levels, the targeted assessment of proteins belonging to the same signaling pathways, and replication in independent cohorts. We also did not test for differences in blood cell type composition between the two groups \[[@pone.0207231.ref061]\], which, if present, could also confound our results to some extent. In addition, we included some patients presenting with highly typical medical and psychiatric comorbidities of CUD in our groups, including those with hypertension, high cholesterol, and non-psychotic psychiatric disorders such as depression and PTSD in our analysis. All of these conditions are thought to be associated with chronic inflammation \[[@pone.0207231.ref062],[@pone.0207231.ref063]\]. While we carefully matched the groups on these potential confounders, we did not have the sample size needed to statistically rule out that they may have influenced our results. We are also not able to establish a direction of causality for relationships between anhedonia, CUD and inflammation--in the absence of either longitudinal data or temperament measures of anhedonia that are assumed to be more stable (e.g. \[[@pone.0207231.ref064]\] we cannot establish whether anhedonia precedes or results from either CUD or inflammation. Another limitation is that our small sample size was not powered to yield FDR-corrected results, raising the possibility type I errors. Although we attempted to protect against this to some extent by taking a bioinformatics approach that tested the likelihood of a *pattern* of changes appearing, use of larger sample sizes in follow-up studies will be important for replication and validation of our preliminary findings, as well as for allowing a statistical correction for the potential confounding clinical variables described above. Likewise, future analyses would significantly benefit from the inclusion of a healthy control group, allowing for further interpretations of the size of gene expression changes between high and low anhedonia groups and the analysis of the potential interaction between the CUD diagnosis and anhedonia. Last, as discussed earlier, integration of these analyses with genotype data (e.g. by expression quantitative trait *loci* analyses) will be particularly important to assess for the involvement of genotypic differences.

Conclusions {#sec010}
===========

In summary, we found that the poor prognostic symptom of anhedonia in CUD is associated with changes in peripheral gene expression in pathways related to inflammatory mechanisms and immune response. This is consistent with evidence from other psychiatric disorders suggesting that anhedonia is related to inflammation, and suggests that anti-inflammatory strategies should be explored in treatment-resistant CUD. Our results form part of an exciting new body of research that uses genome-wide changes in expression to highlight novel directions for treatment research, identifying mechanisms that may not have been a focus of past treatment development efforts.

Supporting information {#sec011}
======================

###### Real-time quantitative PCR (qPCR) validation of microarray results.

Both *IRF1* (A) and *GBP5* (B) show statistically significant correlations between both methods (Spearman's rank order correlation tests) in our sample of cocaine use disorder patients with low (n = 24) and high anhedonia (n = 24).

(TIF)

###### 

Click here for additional data file.

###### Gene expression of interferon regulatory factor 1 (IRF1) and guanylate binding protein 5 (GBP5) measured by quantitative real-time PCR in peripheral blood mononuclear cells from patients with cocaine use disorder with low and high symptoms of anhedonia.

A and B) Between-group comparison of *IRF1* (A) and *GBP5* (B) expression values. Dots represent individual values (normalized for the expression of beta-2-microglobulin (*B2M*) and calculated by the delta delta Ct method) for each subject and lines represent mean ± standard deviation. Comparisons were made with Mann-Whitney U tests. C and D) Spearman's rank-order correlation between total Snaith-Hamilton Pleasure Scale (SHAPS) scores and the expression of *IRF1* (C) and *GBP5* (D) measured by quantitative real-time PCR.

(TIFF)
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Click here for additional data file.

###### Functional annotation clustering.

(DOCX)

###### 

Click here for additional data file.
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